Impact of change in high-density lipoprotein cholesterol from baseline on risk for major cardiovascular events

Advances in Therapy

Volumn 27, Issue 4, 2010, Pages 233-244

  Laitinen, David L ^a   Manthena, Shivaji ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Cardiovascular diseases; Cholesterol; Coronary heart disease; Hdl; Ldl

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH INSURANCE; HUMAN; HYPERTENSION; LABORATORY TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; UNITED STATES;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SOCIOECONOMIC FACTORS;

EID: 77953574296     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0019-4     Document Type: Article

References (51)

1. Davidson M, Meyer PM, Haffner S, et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intimamedia thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008;117:2123-2130.
2. Ferns G, Keti V. HDL-cholesterol modulation and its impact on the management of cardiovascular risk. Ann Clin Biochem. 2008;45:122-128.
3. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J. 2008;84:590- 598.
4. Kim SM, Han JH, Park HS. Prevalence of low HDL-cholesterol levels and associated factors among Koreans. Circ J. 2006;70:820-826.
5. Agoşton-Coldea L, Zdrenghea D, Pop D, Crǎciun A, Rusu ML, Mocan T. Prevalence and particularities of dyslipidaemia in subjects with coronary heart disease. Rom J Intern Med. 2007;45:341-347.
6. Zhang B, Menzin J, Friedman M, Korn JR, Burge RT. Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination. Curr Med Res Opin. 2008;24:2711-2717.
7. Cui Y, Watson DJ, Girman CJ, et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol. 2009;104:829- 834.
8. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-1310.
9. Ghazzal ZB, Dhawan SS, Sheikh A, et al. Usefulness of serum high-density lipoprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. Am J Cardiol. 2009;103:902-906.
10. Belsey J, de Lusignan S, van Vlymen J, Chan T, Hague N. Reducing coronary risk by raising HDL-cholesterol: risk modelling the addition of nicotinic acid to existing therapy. Curr Med Res Opin. 2008;24:2703-2709.
11. Bruckert E, Hansel B. HDL-C is a powerful lipid predictor of cardiovascular diseases. Int J Clin Pract. 2007;61:1905-1913.
12. Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol. 2005;96:50K-58K.
13. Lozano JV, Pallarés V, Cea-Calvo L, et al. Investigators of the PREV-ICTUS Study. Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Curr Med Res Opin. 2008;24:659-670.
14. Koro CE, Bowlin SJ, Stump TE, Sprecher DL, Tierney WM. The independent correlation between highdensity lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J. 2006;151:755.e1-755.e6.
15. Wei L, Murphy MJ, Macdonald TM. Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. Heart. 2006;92:746-751.
16. Alsheikh-Ali AA, Kuvin JT, Karas RH. High-density lipoprotein cholesterol in the cardiovascular equation: does the "good" still count? Atherosclerosis. 2005;180:217-223.
17. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:19L-22L.
18. Toth PP. Should we target HDL cholesterol level in lowering cardiovascular risk? Pol Arch Med Wewn. 2009;119:667-672.
19. Alwaili K, Awan Z, Alshahrani A, Genest J. Highdensity lipoproteins and cardiovascular disease: 2010 update. Expert Rev Cardiovasc Ther. 2010;8:413-423.
20. Lin Y, Mousa SS, Elshourbagy N, Mousa SA. Current status and future directions in lipid management: emphasizing low-density lipoproteins, highdensity lipoproteins, and triglycerides as targets for therapy. Vasc Health Risk Manag. 2010;6:73-85.
21. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. Am Coll Cardiol. 2010;55:1283- 1299.
22. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a predictive factor against coronary heart disease: the Framingham study. Am J Med. 1977;62:707-714.
23. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008;14:S3-S28.
24. Grover SA, Kaouache M, Joseph L, Barter P, Davignon J. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Intern Med. 2009;169:1775-1780.
25. Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16:404-423.
26. Gordon DJ, Probstfield JL, Garrison RJ, et al. Highdensity lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
27. Wierzbicki AS. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin. 2005;21:299-306.
28. Alagona P. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care. 2009;15:S65-S73.
29. Toth PP, Zarotsky V, Sullivan JM, Laitinen D. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. Curr Med Res Opin. 2009;25:1355-1363.
30. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192:432-437.
31. Schachter M. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid. Cardiovasc Drugs Ther. 2005;19:415-422.
32. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham study. Am J Cardiol. 1976;38:46-51.
33. Fornasini M, Brotons C, Sellarès J, et al. Consequences of using different methods to assess cardiovascular risk in primary care. Fam Pract. 2006;23:28-33.
34. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
35. Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest. 2007;37:925-932.
36. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475-1482.
37. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ. 2009;339:b2584.
38. Wilson S, Johnston A, Robson J, et al. Predicting coronary risk in the general population-is it necessary to measure high-density lipoprotein cholesterol? J Cardiovasc Risk. 2003;10:137-141.
39. Simmons RK, Coleman RL, Price HC, et al. Performance of the UK Prospective Diabetes Study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPICNorfolk cohort. Diabetes Care. 2009;32:708-713.
40. Davis WA, Knuiman MW, Davis TM. An Australian cardiovascular risk equation for type 2 diabetes: The Fremantle Diabetes Study. Intern Med J. 2009;Mar 23. Epub ahead of print.
41. Davis WA, Colagiuri S, Davis TM. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Med J Aust. 2009;190:180-184.
42. Vrentzos GE, Papadakis JA, Ganotakis ES, et al. Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease. Int J Clin Pract. 2007;61:1643-1653.
43. Knobel H, Jericó C, Montero M, et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS. 2007;21:452- 457.
44. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005;181:93- 100.
45. Menown IB, Murtagh G, Maher V, Cooney MT, Graham IM, Tomkin G. Dyslipidemia therapy update: the importance of full lipid profile assessment. Adv Ther. 2009;26:711-718.
46. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. Available at: www.cms.hhs.gov/HIPAAGenInfo/Downloads/ HIPAALaw.pdf. Accessed February 12, 2010.
47. Nichols GA, Koro CE, Chan W, et al. The association between fibrate use, change in highdensity lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up. Clin Ther. 2006;28:243-250.
48. Laforest L, Souchet T, Moulin P, et al. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs. Arch Cardiovasc Dis. 2009;102:43-50.
49. Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med. 2008;9:239- 258.
50. Hobson K. Weight-loss surgery to treat diabetes. U.S. News & World Report Posted February 21, 2008. Available at: www.usnews.com/health/ dietfitness/diabetes/articles/2008/02/21/weight-losssurgery-to-treat-diabetes. html. Accessed February 12, 2010.
51. Levy P. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. Postgrad Med. 2009;121:7-12.